Year: 2021

Ensurge Micropower ASA – Investor Presentation – Third Quarter 2021 Report

Written by Customer Service on November 17, 2021. Posted in Public Companies.

Oslo, 17 November 2021 Ensurge Micropower ASA today released an investor presentation to accompany CEO Kevin Barber’s webcast presentation of the Third Quarter 2021 results on Wednesday, 17 November 2021. The presentation is attached and can also be downloaded at https://ensurge.com/investor-relations/presentations-webcasts/About Ensurge Ensurge is Energizing Innovation™ with ultrathin, flexible, and safe energy storage solutions for wearable devices, connected sensors, and beyond. Ensurge’s innovative solid-state lithium battery (SSLB) technology is uniquely positioned to enable the production of powerful, lightweight, and cost-effective rechargeable batteries for diverse applications. The company’s state-of-the-art flexible electronics manufacturing facility, located in the heart of Silicon Valley, combines patented...

DFDS: Q1-3 2021 Interim Report

Written by Customer Service on November 17, 2021. Posted in Earnings Releases And Operating Results.

Company announcement no. 35/2021 SOLID GROWTH IN DEMANDHigh freight revenue growth Supply chain bottlenecks entailed extra costs in Q3 Q3 EBITDA maintained on level with 2020 Q3 2021Revenue up 22% to DKK 4.4bn Strong growth in Mediterranean Slowdown in UK freight flows Passenger numbers still held back by travel restrictions OUTLOOK 2021EBITDA range now expected at DKK 3.3-3.5bn (DKK 3.2-3.6bn) Revenue growth now expected at 23-25% (20-25%) “Meeting our customers’ needs came at a cost in a busy Q3. Looking ahead, we continue on our growth path, supported by our recent acquisitions of HSF Logistics Group and ICT Logistics,” says Torben Carlsen, CEO. KEY FIGURES 2021 2020 2020-21 2019-20 2020DKK m Q3 Q3 Change, % LTM LTM Change, % FY Revenue 4,406 3,598 22.5 16,148 14,218 13.6 13,971EBITDA...

Continued strong performance – good inflow of orders but supply chain under strain

Written by Customer Service on November 17, 2021. Posted in Earnings Releases And Operating Results.

Sales rose by 15.3% to SEK 22,444 million (SEK 19,461 million) Profit after net financial items rose by 45.5% to SEK 3,175 million (SEK 2,182 million) Earnings per share amounted to SEK 1.20 (SEK 0.82) Acquisition of the English companies Heat Trace Holdings and Go Geothermal Ltd“Demand was unusually strong in all three business areas in the first nine months of the year. Market segments with a clear sustainability profile, such as heat pumps, continued to perform well. It is also clear that changes in end consumer behaviour caused by the pandemic have had a positive impact on demand for products designed for home renovation and modernisation. An acute shortage of semiconductors worldwide also means a clear increase in levels of investment in semiconductor production, which benefits our element operations,” says Gerteric Lindquist,...

Better Collective increases organic revenue by 29 percent; strong growth across US assets and media partnerships.

Written by Customer Service on November 17, 2021. Posted in Earnings Releases And Operating Results.

Regulatory Release no. 36/2021 November 17, 2021 Interim report January 1 – September 30, 2021 Highlights third quarter 2021Group Revenue grew by 148% to 45,413 tEUR (Q3 2020: 18,298 tEUR). Organic revenue growth was 29%. September reached a new monthly revenue record of 20,285 tEUR, equal to 45% of the total quarterly revenue.The quarter showed strong underlying growth on all major KPIs, however, revenue was impacted downwards by very low sports win margins in July and August. The sports win margins were negatively affected by larger operators accelerating marketing campaigns (free-bets, retention-bonuses etc.), as well as continued strong NDC performance, where new depositors receive sign-up bonuses. The US business performed strongly with Q3 2021 revenue of >5x compared to Q3 2020 revenue. Revenue for September jumped to...

Release of financial calendar for 2022

Written by Customer Service on November 17, 2021. Posted in Public Companies.

Company Announcement 17 November 2021 Announcement No. 17 Release of financial calendar for 202209 February Deadline for receipt of resolutions for the Annual General Meeting23 February 2021 Annual Report24 March Annual General Meeting18 May Interim Report, Q1 202217 August Interim Report, Q2 202216 November Interim Report, Q3 2022Contact Investor Relations: Michael Nass Nielsen, Head of Investor Relations, tel: +45 2494 1654Media Relations: Louise W. Naldal, Head of Group Communications, tel: +45 2982 0022

Cnova NV appoints new CFO

Written by Customer Service on November 17, 2021. Posted in Public Companies.

Cnova NV appoints new CFO AMSTERDAM – November 17, 2021, 07:45 CET Cnova N.V. (Euronext Paris: CNV; ISIN: NL0010949392) (“Cnova”) today announces the appointment of Mr. Luc Péligry as Chief Financial Officer of Cnova and Cdiscount. Mr. Péligry will also be a member of Cdiscount’s Executive Committee. Mr. Péligry has a strong background in Finance and Management in different business environments, complemented by a wealth of experience in risk management, purchasing, logistics and IT management. Mr. Péligry is 56 years old, graduated from ESSCA, INSEAD and is a qualified Chartered Accountant. Mr. Maxime Dubarry, Deputy CFO of Cnova who has been acting as interim company CFO, will report directly to him. Mr. Péligry will bring his strong experience to support the group’s development by enhancing its performance management across all...

NKT A/S Q3 2021: Earnings increase driven by broad-based growth

Written by Customer Service on November 17, 2021. Posted in Earnings Releases And Operating Results.

Company announcement 17 November 2021Announcement no. 16 NKT A/S Q3 2021: Earnings increase driven by broad-based growth NKT CEO Alexander Kara confirms the preliminary Q3 2021 performance update provided on 19 October 2021: – We have improved our financial performance during 2021, and this continued in Q3 driven by further growth in both NKT and NKT Photonics. It is satisfactory to see that NKT continues to benefit from the green transformation and the successful implementation of improvement initiatives. NKT Photonics continued to grow as the market conditions improved after the negative impact of COVID-19 in 2020. Financial highlights NKT NKT PhotonicsEURm Q3 2021 Q3 2021Revenue 333.2* 18.5Organic growth 10% 10%Operational EBITDA 44.8 3.2Operational EBITDA margin 13.5%* 17.0%* Std. metal prices 2021 financial...

Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer

Written by Customer Service on November 17, 2021. Posted in Public Companies.

New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. Avelumab (BAVENCIO®) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or gastroesophageal junction adenocarcinomas (neoHERIZON) neoHERIZON will assess HER-Vaxx in combination with chemotherapy with or without avelumab in HER-2 positive gastric cancerSYDNEY, Australia., Nov. 17, 2021 (GLOBE NEWSWIRE) — Imugene (ASX: IMU) today announced a new clinical trial supply agreement with Merck KGaA, Darmstadt, Germany (ETR: MRK) and Pfizer Inc. (NYSE: PFE) to evaluate the safety and efficacy of Imugene’s HER-Vaxx, a B-cell activating immunotherapy, in combination with avelumab, an immune checkpoint inhibitor targeting PD-L1, in patients with HER-2 positive gastric cancer. Avelumab, which is marketed as BAVENCIO®, is co-developed...

Santhera and ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone in Duchenne Muscular Dystrophy

Written by Customer Service on November 17, 2021. Posted in Public Companies.

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, November 17, 2021 –Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma (US: private) announce the successful completion of a first pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The FDA considered both the proposed clinical efficacy and safety data sufficient for an NDA filing. Based on the Fast Track Designation for vamorolone, the FDA deemed the plan to pursue a rolling NDA review acceptable. The NDA submission is to commence in Q1-2022. The purpose of the routine Type B pre-NDA meeting was to obtain agreement from the FDA on the sufficiency and adequacy of the clinical data to support an NDA filing of vamorolone for the treatment of DMD. In its conclusions...

PCI Biotech Q3 2021 interim results

Written by Customer Service on November 17, 2021. Posted in Earnings Releases And Operating Results.

Oslo (Norway), 17 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q3 2021 results. Please find enclosed the report and presentation. Highlights fimaChem*Enrolment of patients into the RELASE study is still challenging and fluctuating – Covid-19 has a continued negative impact on the study and with August being a low recruitment month due to the holiday season, only five patients were enrolled in Q3 *Three patients were enrolled into the RELEASE study in October and the company continues to have a strong focus on recruitment, with the emphasis on regular trial management, including overall performance evaluation and site replacement *Thirty patients have per end of October been included in the RELEASE study and the expected timeline for interim analysis remains 2H 2023 *Proactively...

Year: 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals